Stocks › GPCR

Structure Therapeutics Inc.

GPCR·Nasdaq·United States United States·USD
$16.13
-0.99 (-5.78%)
Close · Nov 20, 2026 · Close Prices from Tiingo.com
GPCR
Structure Therapeutics Inc. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
GPCRS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair

Congressional Trades

Recent trades of GPCR by members of U.S. Congress · 1 on record
All congressional trades →
PoliticianStockTypeFiledTraded
Thomas R CarperThomas R CarperSenate · D · DE GPCRStructure Therapeutics Inc. · Stock Sale
$1,001 - $15,000
Nov 2, 2023 Oct 4, 2023 Filing ↗

Whale Activity

Position changes in GPCR reported for 2026-09-30 by 216 institutional filers
Increased: 50New: 23Held: 34Decreased: 57Closed: 44No prior filing: 8
  • Increased50
  • New23
  • Held34
  • Decreased57
  • Closed44
  • No prior filing8
FilerSharesValueChange
WELLINGTON MANAGEMENT GROUP LLP9.8M$305.3Mincreased
FMR LLC9.4M$292.5Mincreased
Avoro Capital Advisors LLC6.6M$205.0Mheld
Janus Henderson Group Ltd.5.1M$158.5M—
Deep Track Capital, LP5.0M$156.3Mincreased
MORGAN STANLEY2.8M$88.1Mincreased
BVF INC/IL2.7M$84.2Mdecreased
RTW INVESTMENTS, LP2.3M$71.4Mincreased
BAKER BROS. ADVISORS LP1.4M$44.8Mheld
ORBIMED ADVISORS LLC1.3M$41.6Mdecreased
Paradigm Biocapital Advisors LP1.3M$40.6Mnew
PRINCIPAL FINANCIAL GROUP INC1.3M$39.6M—

Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.

Insider Trading

Net shares bought (+) or sold (−) on the open market by GPCR insiders, by quarter · Form 4

No open-market insider buys or sells in the last two years.

Recent Insider Transactions

84 transactions on record · newest first
All insider activity →
InsiderTypeSharesPriceValueDate
Coll Crespo BlasCHIEF MEDICAL OFFICER Conversion −12.0K $0.00 $0 Sep 21, 2026 Form 4 ↗
Coll Crespo BlasCHIEF MEDICAL OFFICER Tax withholding −10.6K $11.67 $124K Sep 18, 2026 Form 4 ↗
Lin XichenCHIEF SCIENTIFIC OFFICER Conversion −17.8K $0.00 $0 Sep 1, 2026 Form 4 ↗
Lin XichenCHIEF SCIENTIFIC OFFICER Option exercise +17.8K $0.34 $6K Sep 1, 2026 Form 4 ↗
Lin XichenCHIEF SCIENTIFIC OFFICER Conversion −11.8K $0.00 $0 Aug 18, 2026 Form 4 ↗
Lin XichenCHIEF SCIENTIFIC OFFICER Option exercise +11.8K $0.34 $4K Aug 18, 2026 Form 4 ↗
Berrios John JosephChief Commercial Officer Grant / award +140.8K $0.00 $0 Aug 6, 2026 Form 4 ↗
Lin XichenCHIEF SCIENTIFIC OFFICER Conversion −11.8K $0.00 $0 Aug 4, 2026 Form 4 ↗
Lin XichenCHIEF SCIENTIFIC OFFICER Option exercise +11.8K $0.34 $4K Aug 4, 2026 Form 4 ↗
Lin XichenCHIEF SCIENTIFIC OFFICER Conversion −23.6K $0.00 $0 Jul 14, 2026 Form 4 ↗
Lin XichenCHIEF SCIENTIFIC OFFICER Option exercise +23.6K $0.34 $8K Jul 14, 2026 Form 4 ↗
Lin XichenCHIEF SCIENTIFIC OFFICER Conversion −23.6K $0.00 $0 Jun 25, 2026 Form 4 ↗
Lin XichenCHIEF SCIENTIFIC OFFICER Option exercise +23.6K $0.34 $8K Jun 25, 2026 Form 4 ↗
Lang MatthewCOO & GC Grant / award +184.6K $0.00 $0 Apr 15, 2026 Form 4 ↗
Coll Crespo BlasCHIEF MEDICAL OFFICER Grant / award +75.9K $0.00 $0 Mar 19, 2026 Form 4 ↗
Ma YingliCHIEF TECHNOLOGY OFFICER Grant / award +32.5K $0.00 $0 Mar 19, 2026 Form 4 ↗
Lin XichenCHIEF SCIENTIFIC OFFICER Grant / award +43.4K $0.00 $0 Mar 19, 2026 Form 4 ↗
Yoon JunCHIEF FINANCIAL OFFICER Grant / award +104.1K $0.00 $0 Mar 19, 2026 Form 4 ↗
Hall AshleyChief Development Officer Grant / award +47.7K $0.00 $0 Mar 19, 2026 Form 4 ↗
Stevens Raymond CCHIEF EXECUTIVE OFFICER · Director Grant / award +260.2K $0.00 $0 Mar 19, 2026 Form 4 ↗

Fund Holders

Mutual funds and ETFs holding GPCR · SEC Form N-PORT
FundSharesValue% of fundAs of
Heritage Fund
American Century Mutual Funds, Inc.
967.4K$46.5M0.87%Jul 31, 2026
Fidelity Advisor Growth Opportunities Fund
Fidelity Advisor Series I
733.5K$33.7M0.10%Aug 31, 2026
Global Emerging Markets Fund
Principal Funds, Inc
625.8K$30.1M0.40%Jul 31, 2026
Janus Henderson Global Life Sciences Fund
Janus Investment Fund
549.4K$29.5M0.51%Jun 30, 2026
Fidelity Advisor Biotechnology Fund
Fidelity Advisor Series VII
527.9K$25.4M1.15%Jul 31, 2026
Janus Henderson Triton Fund
Janus Investment Fund
467.1K$25.1M0.42%Jun 30, 2026
Select Biotechnology Portfolio
Fidelity Select Portfolios
542.0K$24.9M0.40%Aug 31, 2026
Select Health Care Portfolio
Fidelity Select Portfolios
500.0K$23.0M0.34%Aug 31, 2026
T. Rowe Price Health Sciences Fund, Inc.419.4K$22.5M0.19%Jun 30, 2026
iShares Biotechnology ETF
iShares Trust
414.3K$22.2M0.24%Jun 30, 2026

Mutual funds and ETFs whose N-PORT filings list GPCR's shares (CUSIP 86366E106), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.

Activist & Passive Stakes

Schedule 13D / 13G beneficial-ownership filings
  • David KroinSCHEDULE 13G/A · passive (13G) · 15.0M shares7.2%
    Nov 16, 2026 · ↗
  • Deep Track Biotechnology Master Fund, Ltd.SCHEDULE 13G/A · passive (13G) · 15.0M shares7.2%
    Nov 16, 2026 · ↗
  • Deep Track Capital, LPSCHEDULE 13G/A · passive (13G) · 15.0M shares7.2%
    Nov 16, 2026 · ↗
  • Wellington Management Company LLPSCHEDULE 13G/A · passive (13G) · 29.3M shares12.8%
    Nov 16, 2026 · ↗
  • Wellington Investment Advisors Holdings LLPSCHEDULE 13G/A · passive (13G) · 29.3M shares13.6%
    Nov 16, 2026 · ↗
  • Wellington Group Holdings LLPSCHEDULE 13G/A · passive (13G) · 29.3M shares13.6%
    Nov 16, 2026 · ↗
  • Wellington Management Group LLPSCHEDULE 13G/A · passive (13G) · 29.3M shares13.6%
    Nov 16, 2026 · ↗
  • Abigail P. JohnsonSCHEDULE 13G/A · passive (13G) · 32.1M shares15.0%
    Nov 5, 2026 · ↗
  • FMR LLCSCHEDULE 13G/A · passive (13G) · 32.1M shares15.0%
    Nov 5, 2026 · ↗
  • Abigail P. JohnsonSCHEDULE 13G/A · passive (13G) · 28.2M shares13.2%
    Aug 6, 2026 · ↗

Corporate Lobbying

Estimated quarterly lobbying spending reported under the LDA, filings naming Structure Therapeutics Inc. as client

No lobbying filings found naming Structure Therapeutics Inc. as the client.

Government Contracts

Federal awards to Structure Therapeutics Inc. · USAspending

No federal contract awards found for Structure Therapeutics Inc..

U.S. Patents

Recent USPTO applications naming Structure Therapeutics Inc.

No USPTO patent applications found for Structure Therapeutics Inc..

Annual Financials

From GPCR's 10-K filings · XBRL
Fiscal yearFY2025FY2024FY2023FY2022
Operating income-$176.6M-$158.2M-$102.8M-$52.6M
Net income-$141.2M-$122.5M-$89.6M-$51.3M
Diluted EPS-$0.80-$0.78-$0.81-$5.51
Operating cash flow-$222.2M-$116.6M-$79.5M-$46.1M
Cash and equivalents$799.6M$169.5M$129.8M$26.1M
Total assets$1.58B$903.3M$482.0M$97.8M
Total liabilities$67.5M$38.5M$29.1M$13.0M
Shareholders' equity$1.52B$864.8M$453.0M-$115.1M

As Structure Therapeutics Inc. tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Feb 26, 2026 ↗

Stock Splits

Every split and reverse split in the price history

No stock splits in GPCR's price history.

Material Events (8-K)

Corporate events filed with the SEC
  • 8-K · Items 2.02, 9.01Results of operationsNov 9, 2026
    EDGAR ↗
  • 8-K · Items 7.01, 8.01, 9.01Reg FD disclosure · Other eventsSep 8, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 9.01Results of operationsAug 6, 2026
    EDGAR ↗
  • 8-K · Items 5.07Shareholder voteJun 18, 2026
    EDGAR ↗
  • 8-K · Items 1.01, 2.02, 8.01, 9.01Material agreement · Results of operations · Other eventsMay 7, 2026
    EDGAR ↗

About Structure Therapeutics Inc.

From SEC EDGAR company records
Industry (SIC 2834)Pharmaceutical Preparations
SectorHealthcare
HeadquartersSOUTH SAN FRANCISCO, CA
IncorporatedE9
Former namesShouTi Inc.